

Serbian Biochemical Society

President: Marija Gavrović-Jankulović

Vice-president: Suzana Jovanović-Šanta

General Secretary: Isidora Protić-Rosić

Treasurer: Milica Popović

Scientific Board

Marija Gavrović-
Jankulović

Mihajlo B. Spasić

Vesna Niketić

Ivanka Karadžić

Svetlana Dinić

Nevena Đukić

Jelena Bašić

Ivan Spasojević

Ivana Beara

Mojca Stojiljković

Andjelka Celić

Željko Popović

Žanka Bojić

Trbojević

Milan Nikolić

Ana Ninić

Adela Pitea

Zupkó István

Vlatka Zoldos

Aleksandra Inić-

Kanada

Tomasz Jurkowski

Yaraslau Dzichenka

Brankica Janković

Sanja Krstić

Organization Committee

Suzana Jovanović-
Šanta

Jelena Purać

Milica Popović

Emilija Svirčev

Miloš Opačić

Milena Dimitrijević

Tatjana Majkić

Sofija Bekić

Diandra Pintać

Isidora Protić-Rosić

Marina Crnković

Maja Marinović

Iva Uzelac

Jovana Drljača

Miloš Avramov

Srdana Đorđievski

Milana Bosanac

Vanja Tatić

Proceedings

Editor: Ivan Spasojević

Technical support: Jelena Korać Jačić

Cover design: Zoran Beloševac

Publisher: Faculty of Chemistry, Serbian Biochemical Society

Printed by: Colorgrafx, Belgrade

Serbian Biochemical Society

Eleventh Conference

Scientific meeting of an international character

September 22nd and 23rd, 2022, Novi Sad, Serbia

“Amazing Biochemistry”

Anticancer properties of cisplatin-naproxen conjugate: free and loaded in SBA-15

Ekatarina Mihajlović^{1*}, Dijana Drača¹, Teodora Komazec¹, Sanja Mijatović¹, Ivana Predarska^{2,3}, Goran N. Kaluderović², Evamarie Hey-Hawkins³, Danijela Maksimović-Ivanić¹

¹*Institute for Biological Research “Siniša Stanković” – National Institute of Republic of Serbia, University of Belgrade, Belgrade, Serbia*

²*Department of Engineering and Natural Sciences, University of Applied Sciences Merseburg, Merseburg, Germany*

³*Leipzig University, Faculty of Chemistry and Mineralogy, Institute of Inorganic Chemistry, Leipzig, Germany*

**e-mail: ekatarina.mihajlovic@ibiss.bg.ac.rs*

To develop anticancer drugs with higher activity and reduced toxicity, cisplatin was used as a scaffold to bear the anti-inflammatory drug naproxen and this conjugate was loaded into silica nanoparticles, SBA-15. In this study, the cytotoxic effect of the free conjugate and the one loaded in SBA-15 was evaluated on different cancer cell lines of mouse origin (B16, 4T1, CT26 and MC38). Treatment with free, as well as with SBA-15-bound conjugate, dose-dependently decreased viability of all cancer cell lines. The viability decrease of B16 cells after treatment with both agents was not caused by apoptosis, but it was followed by caspase activation. On the other hand, treatment with both agents caused significant decrease of B16 cells division rate, indicating the primary cytostatic effect of these agents. Additionally, it was shown that treatment with the free conjugate caused intensified autophagy, while the conjugate loaded into SBA-15 did not show this effect. Since the viability of cells recovered upon the exposure to 3-methyl adenine, detected autophagy serves as a cell death mechanism. Overall, these results indicate that both naked and immobilized conjugates show great potential for cancer treatment.

Acknowledgements

This study was supported by the Ministry of Education, Science and Technological Development of the Republic of Serbia, Grant No. 451-03-68/2022-14/200007.

References

1. Predarska I, Saoud M, Morgan I, Eichhorn T, Kaluderović GN, Hey-Hawkins E. Cisplatin cyclooxygenase inhibitor conjugates, free and immobilised in mesoporous silica SBA-15, prove highly potent against triple-negative MDA-MB-468 breast cancer cell line. *Dalton Trans* 2022;51:857.